Germline DDX41 mutations define a significant entity within adult MDS/AML patients
Germline DDX41 mutations are involved in familial myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-di
Myelodysplastic Syndromes (MDS)
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
PURPOSE:
Over-activation of TGF-b signaling is observed in myelodysplastic syndromes myelodysplastic syndromes: (my
High Hopes Fulfilled for MDS Survivor
I was diagnosed with MDS (RAEB-2 - Refractory Refractory: Not responsive to treatment or cure.
MDS-My Story...so Far! By Barry Parnas
MDS - My Story . . . so far
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
In this article we provide a practical and comprehensive review of myeloid neoplasms with overlapping myelodysplastic (MDS) and myeloproliferative (MPN) features, with emphasis on recent updates in classification, particularly the utility of morphologic, cytogenetic, and molecular findings in better defining and classifying these disease entities.
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Most patients with lower risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A gro
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
PURPOSE OF REVIEW:
Alleviating cytopenias, namely anemia anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count.
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders